Why did the risk picture for menopausal hormone therapy change?
Medically reviewed by
The LovMedSpa medical team, led by Dr. Ahmed Elsoury, MD and Mark Ennett, PhD, CRNA
Last reviewed: July 2026
The 2002 trial that reshaped how a generation of women viewed hormone therapy enrolled participants at an average age of 63, more than a decade past menopause. Later analysis stratified by age at initiation produced a materially different risk and benefit picture for women starting near the transition.
The trial answered a question about starting late
In 2002 the Women's Health Initiative halted one arm of a large randomized trial, and the reporting that followed changed prescribing for twenty years. The important detail was in the population. Average age at enrollment was 63, and many participants were well over a decade past their final menstrual period. The trial answered a question about starting hormone therapy late. It did not answer the question most women are actually asking, which is about starting it at the transition.
The timing hypothesis — and why route matters
Subsequent stratified analyses and dedicated trials of early initiation support what is now called the timing hypothesis. The balance is more favorable for women who begin within roughly ten years of menopause or before age 60, and less favorable when initiation is delayed. Route matters as well. Transdermal estradiol bypasses first-pass hepatic metabolism (the liver's initial processing of an oral dose) and carries a lower venous thromboembolism signal than oral formulations. The progestogen selected for endometrial protection also varies in its risk profile.
What the evidence supports, and what it doesn't
It is worth being specific about what the evidence supports well and what it does not. Relief of vasomotor symptoms is the strongest indication, and the effect is substantial. Preservation of bone density is well established. Prevention of cardiovascular disease is not an approved indication and should not be presented as the reason to start.
The ten-year window is also a guide rather than a wall. Women outside it are not automatically excluded, they simply require a more careful individual assessment. Effective non-hormonal options exist for those who cannot or prefer not to use hormones.
None of this makes hormone therapy universally appropriate. Personal and family history of breast cancer, clotting disorders and cardiovascular disease all change the calculation. It is a physician conversation with labs and history behind it, revisited periodically rather than renewed indefinitely by default.
Common questions
What does the “timing hypothesis” mean?
It refers to the finding, supported by stratified analyses and dedicated trials of early initiation, that the balance of hormone therapy is more favorable for women who begin within roughly ten years of menopause or before age 60, and less favorable when initiation is delayed.
Is starting more than ten years after menopause ruled out?
No. The ten-year window is a guide rather than a wall. Women outside it are not automatically excluded, they simply require a more careful individual assessment. Effective non-hormonal options exist for those who cannot or prefer not to use hormones.
What is hormone therapy well supported for, and what is it not?
Relief of vasomotor symptoms is the strongest indication, and the effect is substantial. Preservation of bone density is well established. Prevention of cardiovascular disease is not an approved indication and should not be presented as the reason to start.
At LovMedSpa, hormone therapy is a physician-led service performed under the oversight of medical director Dr. Ahmed Elsoury, MD (New York and Connecticut) and Mark Ennett, PhD, CRNA (South Florida), with labs and history review, across our Brooklyn, Manhattan, Staten Island, Aventura, and West Farms locations. A consultation is the best way to determine whether hormone therapy fits your history, your timing, and your goals.
This is general information, not medical advice; hormone therapy decisions are made with a physician after a review of labs and personal history.